Alignment Healthcare, Inc. $ALHC Position Decreased by General Atlantic L.P.

General Atlantic L.P. decreased its holdings in shares of Alignment Healthcare, Inc. (NASDAQ:ALHC) by 44.8% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 24,287,227 shares of the company’s stock after selling 19,706,096 shares during the period. Alignment Healthcare comprises approximately 12.7% of General Atlantic L.P.’s holdings, making the stock its 3rd largest position. General Atlantic L.P. owned about 12.14% of Alignment Healthcare worth $423,812,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Royal Bank of Canada lifted its position in Alignment Healthcare by 92.6% during the first quarter. Royal Bank of Canada now owns 92,379 shares of the company’s stock valued at $1,720,000 after purchasing an additional 44,413 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Alignment Healthcare by 4.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 59,557 shares of the company’s stock worth $1,109,000 after buying an additional 2,594 shares in the last quarter. Goldman Sachs Group Inc. increased its position in Alignment Healthcare by 79.1% in the first quarter. Goldman Sachs Group Inc. now owns 972,715 shares of the company’s stock worth $18,112,000 after buying an additional 429,703 shares in the last quarter. Woodline Partners LP bought a new position in shares of Alignment Healthcare in the first quarter worth about $2,142,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Alignment Healthcare by 16.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 307,655 shares of the company’s stock worth $5,729,000 after buying an additional 44,452 shares during the period. 86.19% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Alignment Healthcare

In related news, insider Robert L. Scavo sold 4,044 shares of the stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $17.45, for a total value of $70,567.80. Following the completion of the transaction, the insider owned 498,970 shares of the company’s stock, valued at approximately $8,707,026.50. This trade represents a 0.80% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Andreas P. Wagner sold 21,118 shares of the business’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $18.62, for a total value of $393,217.16. Following the sale, the insider directly owned 148,687 shares in the company, valued at $2,768,551.94. The trade was a 12.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 2,180,140 shares of company stock valued at $42,518,007. Corporate insiders own 7.00% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. Robert W. Baird set a $28.00 price objective on Alignment Healthcare in a research note on Friday, January 30th. Weiss Ratings restated a “sell (d-)” rating on shares of Alignment Healthcare in a research note on Wednesday, January 21st. Piper Sandler lifted their price target on shares of Alignment Healthcare from $20.00 to $30.00 and gave the company an “overweight” rating in a report on Tuesday, January 6th. Wall Street Zen lowered shares of Alignment Healthcare from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. Finally, KeyCorp reissued an “overweight” rating and issued a $28.00 price objective on shares of Alignment Healthcare in a research note on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Alignment Healthcare currently has a consensus rating of “Moderate Buy” and a consensus price target of $24.56.

Alignment Healthcare Stock Down 0.8%

NASDAQ ALHC opened at $16.99 on Friday. The stock has a 50 day moving average price of $20.76 and a 200-day moving average price of $18.73. Alignment Healthcare, Inc. has a one year low of $11.63 and a one year high of $23.87. The company has a debt-to-equity ratio of 1.80, a quick ratio of 1.71 and a current ratio of 1.71. The company has a market capitalization of $3.47 billion, a P/E ratio of -1,697.30, a P/E/G ratio of 2.50 and a beta of 1.18.

Alignment Healthcare (NASDAQ:ALHC) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.10. Alignment Healthcare had a negative net margin of 0.02% and a negative return on equity of 0.49%. The company had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $1 billion. During the same quarter in the previous year, the business posted ($0.16) earnings per share. Alignment Healthcare’s quarterly revenue was up 44.4% on a year-over-year basis. As a group, equities analysts predict that Alignment Healthcare, Inc. will post -0.69 EPS for the current fiscal year.

About Alignment Healthcare

Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.